anne morse, DO, FAASM

Dr. Anne Marie Morse is a board-certified adult neurologist with special qualifications in child neurology and fellowship trained and board-certified in sleep medicine. She is well known across social media as DAMM Good Sleep, where she puts the DAMM (Dr. Anne Marie Morse) in DAMM Good Sleep, but is also recognized as a valued thought leader, changemaker and advocate across healthcare.
Dr. Morse authored the Forbes published Amazon best selling book “Communication in Healthcare: Charting the Course to Better Outcomes with Trust, Respect and Teamwork”. Her blueprint for healthcare transformation and success where effective communication is the compass to achieving optimal transdisciplinary collaboration and patient valued outcomes. Available as hard copy, kindle and now the audiobook (in her own voice). As a part of driving greater impact she has also created the now available digital companion "Communicare-Compendium" which can be accessed at Communicationinhealthcareresources.com or communicare-compendium.com.
In the past decade, Dr. Morse has served in prior or current positions as the director of Child Neurology and Pediatric Sleep Medicine, founder and prior program director of an ACGME approved child neurology residency program, clinical researcher and a leading partner and driver of digital transformation and innovation efforts at Geisinger (Danville, Pennsylvania). As an innovator, Dr. Morse created the first and only responsive, modular remote command center model for sleep and circadian education and screening to improve the recognition and treatment of sleep disorders with Sleep to Be Well and Wake Up and Learn.
As a clinical researcher, she has served as PI or Co-I on 15+ grant funded studies and over a dozen clinical trials, has 60+ peer reviewed publications, more than 75 presented abstracts, and has given over 200 local, regional, national or international presentations.
More broadly she has held roles as a consultant, advisor or steering committee member across numerous leading pharmaceutical companies, investment firms, varying stage biotech ventures and organizations, real world evidence generating platforms, and is also a highly regarded educator with partnerships with leading continuing medical education platforms, such as NeurologyLive, Haymarket Medical Education and DocWire News. In her current role as the chairman of the clinical advisory board, she is facilitating a transformative movement for the company NanoMosaic, in concert with multistakeholder support, to designate NanoMosaic as the leader in multi-omic analysis and value generation through ground breaking cost-effective, accessible, and informative clinical applications in diverse use cases across the healthcare paradigm, capturing unrealized opportunity inclusive of population health to individualization of care strategies. As a trailblazer, innovator and changemaker she has been recognized as a Press Ganey top clinician in the US, top 40 under 40 by modern healthcare and repeatedly recognized as a leading patient advocate.
Dr Morse’s commitment to sleep and circadian health and whole person wellness extends into the community. She established LEAP, Launching the Empowerment of Adolescents Program at Geisinger, which facilitates a peer support network for teens living with chronic disease. She serves as a voluntary advisor or collaborator across multiple non-profit organizations and serves as the chairman of the Board of Directors for the 501(c)3 global advocacy organization, the Wellness, Sleep & Circadian Network (WSCN), where she leads the international efforts for anyone anywhere to “own all 24 hours” to achieve optimal health, wellness and performance. She is also the founder and president of the newly developed 501(c)6, Unifying Care for Advancement Network (UCAN), because When Care Unifies, UCAN Do More.
Ultimately, Dr. Morse envisions a global health learning system that delivers the right care to the right person at the right time.
Financial relationships
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:JazzTopic:IHDate added:10/07/2026Date updated:10/07/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:AvadelTopic:LumryzDate added:10/07/2026Date updated:10/07/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:AvadelTopic:IH and narcolepsyDate added:10/07/2026Date updated:10/07/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:ApnimedTopic:OSADate added:10/07/2026Date updated:10/07/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:AlkermesTopic:Orexin agonist; hypersomnolenceDate added:10/07/2026Date updated:10/07/2026
-
Attribution:SelfType of financial relationship:SpeakerIneligible company:AxsomeTopic:Narcolepsy and osaDate added:10/07/2026Date updated:10/07/2026
-
Attribution:SelfType of financial relationship:SpeakerIneligible company:HarmonyTopic:NarcolepsyDate added:10/07/2026Date updated:10/07/2026
-
Attribution:SelfType of financial relationship:SpeakerIneligible company:AvadelTopic:Lumryz narcolepsyDate added:10/07/2026Date updated:10/07/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:EisaiTopic:Orexin agonistsDate added:10/07/2026Date updated:10/07/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:UCBTopic:EpilepsyDate added:10/07/2026Date updated:10/07/2026

Facebook
X
LinkedIn
Forward